In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Nanna MG, Granger CB. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Annals Of Internal Medicine 2020, 173: jc44. PMID: 33075264, DOI: 10.7326/acpj202010200-044.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeClopidogrelHumansNetwork Meta-AnalysisPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicTicagrelor